The observations made here with Rad21+/− mice indicate that one Rad21 allelic mutation confers a level of IR sensitivity that eclipses that observed in Atm heterozygous mice and accordingly raises the issue that should cancer patients with Rad21 or potentially other cohesin mutations be subjected to RT they may suffer adversely from standard RT protocols. This evidence concerns the gene RAD21 and cancer.